HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) A corrigendum has been published All Versions of this Article: 292/4/E1062    most recent 00450.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Sloth, B. Articles by Astrup, A. Search for Related Content PubMed PubMed Citation Articles by Sloth, B. Articles by Astrup, A.

Effects of PYY_1–36 and PYY_3–36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects

¹Department of Human Nutrition, Centre for Advanced Food Studies, Faculty of Life Sciences, University of Copenhagen, Frederiksberg; and ²Department of Medical Physiology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark

Submitted 25 August 2006 ; accepted in final form 4 December 2006

Peptide YY (PYY)_3–36 has been shown to produce dramatic reductions in energy intake (EI), but no human data exist regarding energy expenditure (EE), glucose and fat metabolism. Nothing is known regarding PYY1-36. To compare effects of PYY_1–36 and PYY_3–36 on appetite, EI, EE, insulin, glucose and free fatty acids (FFA) concentrations, 12 lean and 12 obese males participated in a blinded, randomized, crossover study with 90-min infusions of saline, 0.8 pmol·kg^–1·min^–1 PYY_1–36 and PYY_3–36. Only four participants completed PYY_3–36 infusions because of nausea. Subsequently, six lean and eight obese participants completed 0.2 pmol·kg^–1·min^–1 PYY_3–36 and 1.6 pmol·kg^–1·min^–1 PYY_1–36 infusions. PYY_3–36 at 0.8 pmol·kg^–1·min^–1 produced reduced EI, lower ratings of well-being, increases in FFA, postprandial glucose (only 0.8 pmol·kg^–1·min^–1 PYY_3–36) and insulin concentrations, as well as heart rate and EE (only 0.8 pmol·kg^–1·min^–1 PYY_3–36). PYY_1–36 at 1.6 pmol·kg^–1·min^–1 produced increased heart rate and postprandial insulin response. Ratings of appetite were opposite with infusions of 0.8 and 1.6 pmol·kg^–1·min^–1 PYY_1–36 and seemed to depend on subjects being lean or obese. PYY_3–36 caused increased thermogenesis, lipolysis, postprandial insulin and glucose responses, suggestive of increased sympathoadrenal activity. PYY_1–36 had no effect on EI and no clear effects on appetite but resulted in increased heart rate and postprandial insulin response. However, highest tolerable dose of PYY_1–36 was probably not reached in the present study.

Peptide YY; free fatty acids; insulin sensitivity; arcuate nucleus; neuropeptide Y receptors

This article has been cited by other articles:

				S. R. Bloom, F. P. Kuhajda, I. Laher, X. Pi-Sunyer, G. V. Ronnett, T. M.M. Tan, and D. S. Weigle The Obesity Epidemic: Pharmacological Challenges Mol. Interv., April 1, 2008; 8(2): 82 - 98. [Abstract] [Full Text] [PDF]

				M. H. Tschop and E. Ravussin Peptide YY: obesity's cause and cure? Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1131 - E1133. [Full Text] [PDF]

				B. Sloth, L. Davidsen, J. J. Holst, A. Flint, and A. Astrup Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males Am J Physiol Endocrinol Metab, August 1, 2007; 293(2): E604 - E609. [Abstract] [Full Text] [PDF]

				P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R39 - R46. [Abstract] [Full Text] [PDF]